Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors [scRNA-seq]

ABSTRACT: Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors [scRNA-seq]

PROVIDER: PRJNA1146479 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30190800_1.fastq.gz	Fastqsanger.gz
	SRR30190800_2.fastq.gz	Fastqsanger.gz
	SRR30190900_1.fastq.gz	Fastqsanger.gz
	SRR30190900_2.fastq.gz	Fastqsanger.gz
	SRR30191000_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 3283

Similar Datasets

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors [LCM]

Project description:Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors [LCM]

| PRJNA1146028 | ENA

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors [cell lines]

Project description:Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors [cell lines]

| PRJNA1146030 | ENA

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors [LCM]

Project description:Lung cancer is the leading cause of cancer mortality worldwide. KRAS oncogenes are responsible for at least a quarter of lung adenocarcinomas, the main subtype of lung cancer. After four decades of intense research, selective inhibitors of KRAS oncoproteins are finally reaching the clinic. Yet, their effect on overall survival is limited due to the rapid appearance of drug resistance, a likely consequence of the high intratumoral heterogeneity characteristic of these tumors. In this study, we have attempted to identify those functional alterations that result from KRAS oncoprotein expression during the earliest stages of tumor development. Such functional changes are likely to be maintained during the entire process of tumor progression regardless of additional co-occurring mutations. Single-cell RNA sequencing analysis of murine alveolar type 2 cells expressing a resident Kras oncogene revealed impairment of the type I interferon pathway, a feature maintained throughout tumor progression. This alteration was also present in advanced murine and human tumors harboring additional mutations in the p53 or LKB1 tumor suppressors. Restoration of type I interferon (IFN) signaling by IFN-beta or constitutive active stimulator of interferon genes (STING) expression had a profound influence on the tumor microenvironment, switching them from immunologically “cold” to immunologically “hot” tumors. Therefore, enhancement of the type I IFN pathway predisposes KRAS mutant lung tumors to immunotherapy treatments, regardless of co-occurring mutations in p53 or LKB1.

2024-08-12 | GSE274351 | GEO

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors [scRNA-seq]

2024-08-12 | GSE274477 | GEO

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors [cell lines]

2024-08-12 | GSE274352 | GEO

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.

Project description: Not available

| S-EPMC11388366 | biostudies-literature

Radiation combined with KRAS-MEK inhibitors enhances anticancer immunity in KRAS-mutated tumor models

Project description:Radiation combined with KRAS-MEK inhibitors enhances anticancer immunity in KRAS-mutated tumor models

| PRJNA862365 | ENA

KRAS G12C inhibition combined with CD47 and immune checkpoint blockage overcomes intrinsic resistance to concomitant KRAS G12C and immune checkpoint inhibitor therapy

Project description:KRAS G12C inhibition combined with CD47 and immune checkpoint blockage overcomes intrinsic resistance to concomitant KRAS G12C and immune checkpoint inhibitor therapy

| PRJNA1234660 | ENA

STUB1 is an intracellular checkpoint for interferon gamma sensing

Project description:STUB1 is an intracellular checkpoint for interferon gamma sensing

| PRJNA854156 | ENA

Enhancer Remodeling-Driven Mevalonate Pathway Confers Resistance to KRAS Inhibitor in Colorectal Cancer

Project description:This study investigates the resistance mechanisms to pan-KRAS inhibitors in colorectal cancer (CRC). We established a panel of patient-derived organoids (PDOs) and cell lines with differential sensitivity to pan-KRAS inhibitors. Integrated epigenomic (ChIP-seq for H3K27ac and H3K4me3) and transcriptomic (RNA-seq) profiling revealed that enhancer remodeling drives compensatory activation of the mevalonate (MVA) pathway in resistant models. The MVA pathway upregulation facilitates KRAS membrane trafficking via protein farnesylation, thereby sustaining ERK activation and conferring resistance to KRAS inhibitors. Pharmacological inhibition of the MVA pathway using statins restores therapeutic sensitivity and enhances efficacy of KRAS inhibitors in cellular, PDO, and PDX models.

2025-11-01 | GSE306909 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data